Literature DB >> 20610332

Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy.

Alberto Cagigi1, Anna Nilsson, Simone Pensieroso, Francesca Chiodi.   

Abstract

Although HIV-1 infection does not directly target B cells, B-cell numbers are reduced and their function is impaired during HIV infection. Antibody titres against antigens previously encountered through vaccination or natural infection are low in patients with HIV. Intrinsic B-cell defects might be involved in the impairment of humoral immunity during early HIV infection. Abnormal T-cell activation and the altered expression of molecules involved in the B-cell homing process cause dysfunctional interaction between T and B cells in the germinal centres of lymphoid tissues, which might impair B-cell responses during HIV infection. Class-switch recombination is also impaired in individuals with HIV. Protective immune responses against T-cell-dependent antigens, including influenza antigens, rely on the production of neutralising antibodies. Impaired B-cell responses during HIV infection could therefore hamper the effectiveness of vaccinations against seasonal influenza or the new pandemic influenza A H1N1 vaccines in individuals with HIV. By maintaining B-cell responses, highly active antiretroviral therapy might improve the efficacy of influenza vaccines in individuals with HIV. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610332     DOI: 10.1016/S1473-3099(10)70117-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  43 in total

1.  New therapy to revert dysfunctional antibody responses during HIV-1 infection.

Authors:  Francesca Chiodi
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Authors:  Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

Review 3.  Premature B-cell senescence as a consequence of chronic immune activation.

Authors:  Paolo Palma; Stefano Rinaldi; Nicola Cotugno; Veronica Santilli; Savita Pahwa; Paolo Rossi; Alberto Cagigi
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

Review 5.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

7.  Histoarchitectural Deterioration of Lymphoid Tissues in HIV-1 Infection and in Aging.

Authors:  Robert L Furler; Kevin L Newcombe; Perla M Del Rio Estrada; Gustavo Reyes-Terán; Christel H Uittenbogaart; Douglas F Nixon
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-07       Impact factor: 2.205

8.  CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Authors:  Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

9.  Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment.

Authors:  Silvia Della Bella; Adriano Taddeo; Elena Colombo; Lucia Brambilla; Monica Bellinvia; Fabrizio Pregliasco; Monica Cappelletti; Maria Luisa Calabrò; Maria Luisa Villa
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.